摘要
目的观察瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效及安全性,为冠心病的治疗提供参考依据。方法160例冠心病患者随机分为两组,每组各80例,其中观察组采用瑞舒伐他汀治疗,口服10 mg/次,1次/d,对照组采用阿托伐他汀治疗,口服20mg/次,1次/d,疗程6个月。测量两组治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、颈动脉内膜中层厚度(IMT),并进行统计学分析。结果两组患者有效率及不良事件发生率差异无统计学意义(P>0.05),两组患者治疗后TC、TG、LDL-C、hs-CRP、Hcy、颈动脉IMT水平低于治疗前,HDL-C水平高于治疗前,差异有统计学意义(P<0.05),观察组TC、TG、LDL-C、hs-CRP、Hcy、颈动脉IMT水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀与阿托伐他汀均能有效改善冠心病患者血脂水平,降低hsCRP、Hcy、颈动脉IMT水平,且瑞舒伐他汀治疗效果比阿托伐他汀更显著。
Objective To study the efficacy and safety of rosuvastatin and atorvastatin in treatment of patients with coronary heart disease for providing references to treating coronary heart disease.Metheds 160 patients with coronary heart disease were divided into observation group and control group,80 patients in each group.The observation group took rosuvastatin tablet,10 mg once a day and the control group took atorvastatin tablet,20 mg once a day.The course of treatment for the two groups was 6 months. Cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol（ HDL-C）, high-sensitivity C-reactive protein （ hs- CRP）, homocysteine （ Hcy）, carotid artery intima - media thickness （IMT） of patients in the two groups were tested before and after treatment and the data were analyzed statistically.Results There were no significant difference in effective rate and incidence of adverse reactions between the two groups （P〉0.05） .After treatment, TC, TG, LDL-C, hs- CRP, Hcy and IMT in the two groups were significantly lower than those before treatment,and HDL-C in the two groups were significantly higher than that before treatment,which had statistical significance（P〈0.05）.The TC,TG, LDL-C, hs-CRP, Hcy and I MT in the observation group were significantly lower than those in the control group, but HDL-C was significantly higher than that in the control group,which had statistical significance（P〈0.05）.Conclusion Rosuvastatin and atorvastatin can effectively improve the condition of blood lipid in patients with coronary heart heart disease and reduce the levels of hs-CRP, Hcy and carotid IMT,additionally rosuvastatin is more effective than atorvastatin.
出处
《湖北民族学院学报（医学版）》
2017年第3期17-19,23,共4页
Journal of Hubei Minzu University(Medical Edition)
关键词
冠心病
瑞舒伐他汀
阿托伐他汀
疗效
安全性
coronary heart disease
rosuvastain
atorvastatin
efficacy
safety
